We found a negative correlation of the serum levels of HMGB1 in glioma patients with both percentages of CD14+ TREM-1+ cells (P = 0.049) and TREM-1/TREM-2 ratio (P = 0.004) (Table 2). This evidence concerns the gene CD14 and central nervous system cancer.